Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pegylated SN-38 Conjugate PLX038

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Platinum-Resistant Fallopian Tube CarcinomaActive, not recruiting

Platinum-Resistant Fallopian Tube CarcinomaPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q1 2030

Phase 2Active, not recruiting

Platinum-Resistant Fallopian Tube Carcinoma

NCT05465941

Clinical

Trials by Indication[1]

Platinum-Resistant Fallopian Tube Carcinoma1 trial

Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Active, not recruiting·MMayo Clinic·Phase 2·NCT05465941·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pegylated SN-38 Conjugate PLX038. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated SN-38 Conjugate PLX038 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated SN-38 Conjugate PLX038. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMayo Clinic

Related News